TI
BDTX icon

Trexquant Investment’s Black Diamond Therapeutics BDTX Stock Holding History

Trexquant Investment’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-135,868
Closed -$591K – 1556
2024
Q3 		$591K Buy
+135,868
New +$739K 0.01% 1210
2022
Q1 		– Sell
-34,809
Closed -$186K – 1360
2021
Q4 		$186K Buy
+34,809
New +$243K 0.01% 1168
2021
Q3 		– Sell
-12,826
Closed -$156K – 1131
2021
Q2 		$156K Buy
12,826
+1,078
+9% +$21.3K 0.01% 963
2021
Q1 		$285K Buy
11,748
+1,219
+12% +$32.9K 0.03% 779
2020
Q4 		$337K Buy
+10,529
New +$346K 0.04% 626

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Trexquant Investment's BDTX Position: Q4 2024 in Review

Trexquant Investment sold out of Black Diamond Therapeutics (BDTX) in Q4 2024, closing a stake of 135,868 shares — an estimated $591K sold.

Trexquant Investment first reported a position in BDTX in Q4 2020 and held it in 5 quarters. The position peaked at $591K in Q3 2024. 87 funds tracked by Wall St. Rank hold BDTX as of Q4 2024.

  • Trexquant Investment reported no remaining Black Diamond Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Trexquant Investment sold 135,868 Black Diamond Therapeutics shares in Q4 2024, an estimated $591K.
  • Trexquant Investment first reported a position in Black Diamond Therapeutics in Q4 2020 and held it in 5 quarters.
  • Trexquant Investment's Black Diamond Therapeutics position peaked at $591K in Q3 2024.
  • 87 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2024.

Based on Trexquant Investment's 13F filing for Q4 2024, filed 12 Feb 2025.